Please login to the form below
Cerdelga
This page shows the latest Cerdelga news and features for those working in and with pharma, biotech and healthcare.
R&D productivity takes off
Among these, notable examples include PTC Therapeutics' Translarna (ataluren) - the first medicine approved for the treatment of Duchenne muscular dystrophy (DMD) - and Sanofi/Genzyme's Cerdelga (eliglustat) for Gaucher disease, a
Latest news
-
Genzyme's oral Gaucher drug cleared in Europe
In contrast, Cerdelga and Zavesca are glucosylceramide synthase inhibitors, which work by reducing the substrate for the deficient enzyme. ... Analysts have suggested Cerdelga could achieve sales upwards of $350m in 2017 and eventually rival Cerezyme in
-
Orphan drugs in latest CHMP recommendations
advisers. The Committee for Medicinal Products for Human Use (CHMP) backed Genzyme's Cerdelga (eliglustat) and Boehringer Ingelheim's Ofev (nintedanib) in its latest round of opinions - which are usually followed ... Cerdelga has demonstrated it is as
-
Sanofi plans 18 new product launches by 2020
The remainder of its growth portfolio are Cerdelga (eliglustat) for Gaucher disease - the only approved oral, first-line therapy for the rare genetic disease, Lemtrada (alemtuzumab) for multiple sclerosis and sarilumab,
-
FDA gives green light to Genzyme’s oral Gaucher drug
the possibility that Cerdelga could be used alongside Cerezyme as a combination regimen. ... The company said it wants a pricing strategy that does not drive patients towards either Cerezyme or Cerdelga, making the choice of therapy a purely clinical
More from news
Approximately 2 fully matching, plus 3 partially matching documents found.
Latest Intelligence
-
Assessing the impact of rarity on French HTA and pricing decisions
Examples include Galafold (ASMR 4) and Cerdelga (ASMR 5). The relatively high prices of these products suggest that the relationship between ASMR and ATC includes other factors such as disease prevalence,
-
Deal Watch table for November 2014
Cerdelga (eliglustat) sold by Vertex. Acquisition 75% royalty stream. 66. Five Prime Therapeutics / BMS.
-
Pharma deals during November 2014
In another similar deal, PDL Biopharma acquired the 75% of the University of Michigan's worldwide royalty interest in Cerdelga (eliglustat) for $66m. ... Cerdelga, an oral therapy for adult patients with Gaucher disease type 1, was developed by Genzyme
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
- Pfizer’s RSV vaccine granted MHRA approval to protect infants and older adults
- Novavax’s updated COVID-19 vaccine granted Emergency Use Listing by WHO
- FDA to investigate risk of T-cell malignancy from CAR-T cell immunotherapies
- Boehringer Ingelheim and IBM announce AI antibody drug discovery partnership
- New blood test to reduce heart attacks and death rates in A&E heart patients
- Clairvoyant commercialisation
No results were found
PMHub
KVA
KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...
Latest intelligence
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
- The rise of digital healthcare – fuelled by open innovation in healthtech hubs
- How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of drug development...
